Objectives: The objectives of this study were (1) to compare age at death and the intensity and cost of medical treatment for infants diagnosed prenatally or postnatally with congenital anomalies considered to be lethal.
Introduction
With advances in prenatal screening, congenital malformations are increasingly diagnosed in utero.
1 Physicians and parents of fetuses and infants with severe anomalies face an array of decisions, including whether to continue an affected pregnancy and, if so, how aggressively to treat the infant after birth. Reports and professional communication suggest that disagreement over how much intervention is appropriate is common, particularly regarding therapies for infants with anomalies that the medical profession considers lethal. [2] [3] [4] Hope, disbelief, or uncertainty on the part of physicians or parents about an infant's diagnosis or prognosis and unwillingness to withhold potentially beneficial therapy may lead to aggressive treatment despite the burdens of intensive care. Although individual cases generate distress, and occasionally publicity, little systematic data exist to evaluate the scope of the issue. We do not know the extent and cost of treatment provided to newborns with anomalies classified as lethal, whether or how long aggressive intervention prolongs their lives and how prenatal diagnosis affects the outcome of liveborn infants. Such data are needed for prudent health care policy and practice, because it is morally and socially problematic to use resources and increase patients' suffering without providing medical benefit. It is equally problematic to categorize a condition as lethal, if by doing so the use of potentially beneficial therapy is foreclosed. To begin to address these issues, we assembled a cohort of fetuses and infants with congenital anomalies considered to be lethal and determined rates of pregnancy termination and live birth, intensity and cost of medical treatment provided during infants' neonatal hospitalization, length of survival, whether aggressive treatment was associated with longer life, and whether the outcomes of prenatally and postnatally diagnosed infants differed.
Methods
We used a two-step process to generate a list of congenital anomalies that medical professionals classify as lethal. First, we elicited the expert opinion of knowledgeable clinicians (three perinatologists, three neonatologists, one geneticist and two genetics counselors) who reviewed International Classification of Diseases, Ninth Revision codes (ICD-9 codes 740 to 759) 5 and identified the congenital diagnoses they considered lethal. We then performed MEDLINE and Google searches of the diagnoses listed by two-thirds or more of the clinicians, reviewed articles, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] reference texts 17 and websites, 18, 19 and retained those diagnoses that were consistently reported to be associated with death before a year of life in nearly all (X85%, when statistics were available) cases. We excluded conjoined twins because of the confounding effect of one infant's condition on the other.
The University of North Carolina Hospitals (UNCH) is a regional referral center providing comprehensive prenatal and neonatal care. We searched UNCH databases for all fetuses and neonates (infants aged <28 days) with lethal congenital anomalies who were diagnosed or treated at UNCH from 1 January 1998 through 31 December 2003.
Dates of an initial and a confirmed diagnosis were determined for each subject. Confirmation required a definitive test or accepted diagnostic method. For example, Trisomy 18 might initially be suspected from choroid plexus cysts and clenched fists on prenatal ultrasound, and confirmed by karyotype. We categorized subjects as prenatally diagnosed when the lethal condition was confirmed >24 h before delivery, perinatally diagnosed when the lethal condition was confirmed <24 h before delivery, or postnatally diagnosed when the lethal condition was confirmed at or after delivery.
We obtained sociodemographic and clinical data from UNCH records, the North Carolina Birth Defects Registry and North Carolina Vital Records. Gestational age was based on the best obstetrical estimate. We defined pregnancy termination as the elective interruption of pregnancy before 37 weeks of gestation, with the intention of not providing treatment. We used calendar dates to determine the age at death, counting the day of delivery as day zero.
The intensity of treatment provided to infants during their neonatal hospitalization was quantified using the Neonatal Therapeutic Intervention Scoring System (NTISS) 20 (possible scores from 0 to 100). One author (AMC) scored each infant twice (Pearson coefficient for intraobserver variability ¼ 0.98). NTISS scores were recorded daily from delivery through the first 2 weeks of life, then weekly until death or discharge, whichever came first. For each infant, we calculated a total (cumulative) NTISS score and an average daily NTISS score.
We used direct costs from UNCH accounting records to derive a minimum estimate of the cost of each infant's treatment. We did not include indirect costs or physicians' charges because of their variable relationship to true costs. For infants born at or discharged to outlying hospitals, we included the direct cost of transport to or from UNCH, but not the costs incurred at the outlying facility.
This study was approved by institutional review boards at UNCH and the North Carolina Birth Defects Registry.
Statistical analysis
We used two-tailed Student t-tests and Fisher exact tests to compare continuous and categorical variables, respectively. We used Kendall rank correlation to analyze the relationship between treatment intensity and age at death. To compare prenatally and postnatally diagnosed infants, we used Kaplan-Meier survival curves with a Gehan-Breslow (generalized Wilcoxon) test because of the steep early fall-off of survivors in both groups. We used a Cox proportional hazards regression model to adjust for treatment intensity in the first 10 days of life.
Results
We identified 199 fetuses and neonates with congenital anomalies classified as lethal. Six fetuses were lost to follow-up. We excluded one infant whose prenatal diagnosis was discovered on the day of birth to be erroneous. The remaining 192 fetuses and neonates constituted the study cohort.
A total of 160 fetuses (83%) were diagnosed prenatally, 2 (1%) perinatally and 30 infants (16%) were diagnosed postnatally. Five (17%) of the postnatally diagnosed infants were initially suspected to have a lethal condition prenatally, but it was not confirmed until after birth. Counting these five infants in the prenatally diagnosed group would not have altered the study's findings. Because of the small size of the perinatally diagnosed group, we did not analyze it in between-group comparisons.
Supplementary Figure 1 lists the lethal congenital anomalies and their distribution among the study cohort. Aneuploidy was most common, followed by central nervous system anomalies. Rates of pregnancy termination were highest for central nervous system anomalies and for aneuploidy. Among liveborn infants, there were more renal disorders in the prenatally diagnosed group and more aneuploidy in the postnatally diagnosed group (P ¼ 0.06 for difference in distribution of diagnoses).
Supplementary Table 1 outlines the sociodemographic and clinical characteristics of the study cohort. In the prenatally diagnosed group, 115 (72%) pregnancies were terminated, 19 (12%) fetuses died in utero or were stillborn and 26 (16%) infants were liveborn. Six (5%) of the terminations occurred after a lethal condition was suspected, but before it was confirmed. White women were more likely to terminate their pregnancies than were Black or Hispanic women.
Among women who delivered liveborn infants, mothers of prenatally diagnosed infants were less educated than mothers of postnatally diagnosed infants. There were high rates of cesarean delivery in both groups; however, <20% of mothers with prenatally diagnosed infants underwent primary cesarean sections, compared with nearly half of those with postnatally diagnosed infants. Infants in both the prenatally and postnatally diagnosed groups had similar mean gestational ages, birth weights and 1-min Apgar scores, but postnatally diagnosed infants had higher 5-min Apgar scores. Infants diagnosed prenatally were more likely to be born at a tertiary care hospital. Figure 1 depicts the intensity of medical treatment provided to infants at delivery and during their neonatal hospitalization. Infants diagnosed prenatally received less treatment overall (median total NTISS score 10.0 versus 73.5; P ¼ 0.04) and less intense treatment each day they survived or remained hospitalized (median average daily NTISS score 8.3 versus 14.0; P ¼ 0.02).
Three infants were lost to follow-up after hospital discharge. The median age at death for the remaining 55 liveborn infants was 3 days (range <1 to >730 days). A total of 41 infants (75%) died before 10 days of age, 47 (85%) died before 60 days of age and 50 (90%) died before 4 months of age. Two infants survived for >2 years. Both had hydranencephaly diagnosed postnatally. Figure 2 compares the survival curves of prenatally and postnatally diagnosed infants. Prenatally diagnosed infants died sooner (median age at death <1 versus 4 days; range <1 to 205 days versus <1 to >730 days; intraquartile range (IQR) <1 to 6 days versus 2 to 10 days; P ¼ 0.01). Of the prenatally diagnosed group, 58% died on the day of delivery, compared with 10% of the postnatally diagnosed group. By the tenth day of life, the survival curves of the two groups were similar. Among infants dying in the first 10 days of life, postnatal diagnosis was associated with older age at death, even after adjusting for average daily NTISS score (hazard ratio ¼ 0.22, 95% confidence interval ¼ 0.10 to 0.50; P ¼ <0.001). We found no correlation between average daily treatment intensity and length of survival in the cohort as a whole (Figure 3 ; r ¼ À0.04, P ¼ 0.66), nor in the prenatally diagnosed group analyzed separately (r ¼ 0, P ¼ 0.98). In the postnatally Includes the two perinatally diagnosed infants, who had total NTISS scores of 0 and 188 and average daily NTISS scores of 0 and 15.7. Figure 2 Kaplan-Meier survival curves for liveborn prenatally and postnatally diagnosed infants with lethal congenital anomalies. Two prenatally diagnosed infants (one with anencephaly and one with multicystic kidneys and anhydramnios) and one postnatally diagnosed infant (with Trisomy 13) were lost to follow-up and were not included in the Kaplan-Meier curves. Two postnatally diagnosed infants survived for >230 days and remained alive at 2 years of age, the duration of follow-up for this study. One perinatally diagnosed infant died on the day of delivery (day 0); the other perinatally diagnosed infant died at 537 days of age. *P-value was calculated with the Gehan-Breslow (generalized Wilcoxon) test for significance. Figure 3 Relationship between treatment intensity measured by average daily Neonatal Therapeutic Intervention Scoring System (NTISS) score and length of survival for all liveborn infants with lethal congenital anomalies. *P-value and correlation coefficient (r) were calculated with the Kendall rank correlation. diagnosed group, there was an inverse relationship between treatment intensity and length of survival, with infants who received more intense treatment dying sooner than those who received less intense treatment (r ¼ À0.38, P ¼ 0.01).
The median cost of medical treatment from delivery until death or discharge for the cohort as a whole was $4541 (range $0 to $70 130; IQR $1493 to $10 509). On average, each hospital day cost a median of $1476. Prenatally diagnosed infants had lower average daily hospital costs than postnatally diagnosed infants ($1004 versus $1531; P ¼ 0.01) and lower total costs of hospitalization ($1550 versus $8474; range $0 to $35 346 versus $1260 to $70 130; IQR $386 to $2883 versus $4372 to $12 284; P ¼ 0.03).
Discussion
Infants with anomalies classified as lethal present medical, ethical and legal challenges. Prognostication and management are based largely on case series suggesting that nearly all affected infants die shortly after birth. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] However, reports of occasional long-term survivors [21] [22] [23] [24] and of decreased mortality with intensive care 25, 26 raise questions about the use of the term 'lethal' in this context. Especially, as parents access available knowledge, policies that limit medical treatment are being questioned. Differences of opinion arise about how aggressively to treat these infants and whether to honor parental requests for intervention. 4 Little systematic information exists about the scope of the problem or to adjudicate disputes. 13 For infants in our cohort, the median age at death was 3 days. In total, 75% died within 10 days and 90% died within 4 months of birth. As long as the term 'lethal' is explicitly understood to encompass a few long-term survivors, these findings support the categorization of the conditions on our list as lethal. However, two of four infants with hydranencephaly lived longer than 2 years, suggesting that classifying this diagnosis as 'lethal' should be reconsidered.
Nearly three-quarters of the pregnancies in this cohort were electively terminated. Mothers of prenatally diagnosed liveborn infants were less likely than mothers of postnatally diagnosed infants to undergo a primary cesarean section and more likely to deliver at a tertiary care center. This suggests that even women who did not elect to terminate their pregnancy derived some benefit from prenatal diagnosis, although we cannot say whether parents, on balance, felt that having foreknowledge of their infant's condition was beneficial or harmful.
We found that prenatally diagnosed infants died sooner than postnatally diagnosed infants, at a median of <1 day versus 4 days, and that they received less intense treatment, in total and on any given hospital day. The difference between an NTISS score of 8.3 and 14, the median average daily treatment intensities for prenatally and postnatally diagnosed infants, is the difference between, for example, receiving only peripheral intravenous fluids and being mechanically ventilated with a central line. Given that 75% of these infants died by 10 days of age, and that after day 10 there was no difference in the survival curves of prenatally and postnatally diagnosed infants, we suggest that the four additional days that postnatally diagnosed infants survived, coupled with the more aggressive treatment they received, can reasonably be categorized as 'prolonged dying. 27, 28 At a time when death was foreseeable, imminent and highly likely, prenatal diagnosis may have facilitated earlier and better decision making by parents and physicians, possibly by mitigating diagnostic and prognostic uncertainty, shortening the time after birth it takes to acknowledge a dire prognosis, and/or reducing conflict among decision makers.
Recently, the authors of a few small case series reported increased neonatal and 1-year survival of infants with trisomy 18 or 13, and attributed this to aggressive medical and surgical intervention. 25, 26 These investigators did not employ contemporary comparison groups receiving lesser amounts of treatment, but instead compared their outcomes with the medical literature or with previous epochs at their institutions. In contrast, in our cohort, the receipt of more intense treatment did not correlate with longer survival. It may be that newborns with lethal anomalies who need very intense therapy are often too sick to benefit from it, or perhaps the need for aggressive therapies hastens the recognition by parents and physicians that an infant is moribund, causing them to withdraw medical support sooner. How long these infants survive may have more to do with the kind and severity of their underlying conditions than with the treatment they receive. The inverse relationship between treatment intensity and age at death in postnatally diagnosed infants indicates that it was not the infants who received maximal medical intervention who were responsible for the older age at death in that group.
The strengths of this study lie in its cohort design, which provided systematic, longitudinal data on outcomes, and its evaluation of treatment intensityFa parameter vital for adequate ethical and policy analyses. To our knowledge, it is the first study to compare outcomes of prenatally and postnatally diagnosed infants with lethal congenital anomalies.
Limitations include the use of a cohort from a single center, small numbers of liveborn infants, and lack of data on intensity and cost of treatment during pregnancy and after hospital discharge. How much costs would increase if subsequent treatment of survivors was included, or whether the gap in resource consumption between prenatally and postnatally diagnosed infants would narrow if physician fees and prenatal diagnostic procedures were tallied is unclear. Finally, it is possible that factors other than the timing of diagnosis were responsible for the differences we found between prenatally and postnatally diagnosed infants. The case mix in the two groups was not identical, so differences in their outcomes could reflect variations in their diagnoses or disease severity. Mothers of postnatally diagnosed infants may have refused prenatal studies because they did not plan to act on the results, and if so, certain attitudes or characteristicsFfor example, religious beliefsFmay have driven differences in treatment intensity, rather than prenatal diagnosis itself. Our finding that prenatal diagnosis may benefit mothers and infants apart from termination of pregnancy should contribute to counseling in this context.
Ultimately, we believe that our data support an ethical stance in which treatment options offered to parents in the neonatal period are limited to non-intensive modalities. 3, 4 Causing pain or suffering without commensurate benefit is morally problematic. As highly aggressive treatment conferred no survival advantage in this population, unless future reports provide evidence to the contrary, modalities such as mechanical ventilation or dialysis, for example, need not be offered or employed. It may be appropriate to provide lower levels of medical care, however, at parents' request, or to broaden treatment options if an infant turns out to be a long-term survivor. Our findings should be confirmed with data from multiple centers before instituting broad policy recommendations. Focusing on the outcomes and response to treatment of specific lethal disorders is a goal for future research.
